Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes

Ginger S. Carls,[1] Edward Tuttle,[1] Ruo-Ding Tan,[1] Johnny Huynh,[1] John Yee,[2] Steven V. Edelman,[3,4,5] and William H. Polonsky[6,7]

OBJECTIVE

The objective of this study was to estimate and explain the gap between clinical efficacy and real-world (RW) effectiveness of type 2 diabetes medications.

RESEARCH DESIGN AND METHODS

This mixed-methods quasi-experimental study used retrospective claims (Optum/Humedica) to compare the change in HbA_{1c} of RW patients with type 2 diabetes 12 months after starting a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase 4 (DPP-4) inhibitor with published findings from randomized controlled trials (RCTs) evaluating these drugs. Selected RW patients were similar to RCT patients, and regression analysis was used in the RW data to adjust for differences between poorly adherent and adherent patients to explain why RCT and RW findings may differ.

RESULTS

RW patients initiating a GLP-1 RA (n = 221) or a DPP-4 (n = 652) experienced smaller reductions in HbA_{1c} (GLP-1 RA: −0.52% [−6 mmol/mol], DPP-4: −0.51% [−6 mmol/mol]) than reported in RCTs (−1.30% [−14 mmol/mol] from seven GLP-1 RA RCTs, n = 2,600; −0.68% [−8 mmol/mol] from four DPP-4 RCTs, n = 1,889). Baseline HbA_{1c}, additional medications, and adherence were significant explanatory factors in the RW HbA_{1c} change. Modeled estimates of RCT efficacy (−1.04% GLP-1 RA [−12 mmol/mol], −0.69% DPP-4 [−8 mmol/mol]) were within the RCTs' reported range (GLP-1 RA: −0.84% to −1.60% [−9 to −18 mmol/mol], DPP-4: −0.47% to −0.90% [−5 to −10 mmol/mol]). Poor medication adherence accounted for approximately three-fourths of the gap between RW and expected RCT results (gap = 0.51% [6 mmol/mol] GLP-1 RA; 0.18% [3 mmol/mol] DPP-4).

CONCLUSIONS

Poor medication adherence is primarily why RW effectiveness is significantly less than RCT efficacy, suggesting an urgent need to effectively address adherence among patients with type 2 diabetes.

[1]Analysis Group, Menlo Park, CA
[2]Intarcia Therapeutics, Boston, MA
[3]Division of Endocrinology and Metabolism, School of Medicine, University of California, San Diego, San Diego, CA
[4]Taking Control of Your Diabetes, Del Mar, CA
[5]Veterans Affairs Medical Center, San Diego, CA
[6]Department of Psychiatry, University of California, San Diego, San Diego, CA
[7]Behavioral Diabetes Institute, San Diego, CA

Corresponding author: Ruo-Ding Tan, ruo-ding.tan@analysisgroup.com.

Despite the development of nearly 40 new medications for type 2 diabetes during the past decade, only approximately half of adults with type 2 diabetes in the U.S. achieve a general target glycated hemoglobin (HbA$_{1c}$) of <7% (<53 mmol/mol), a proportion that has not improved during the last 10 years (1–3). The efficacy of these new medications has been demonstrated in many randomized controlled trials (RCTs) (4,5). However, real-world (RW) medications use may differ from use in RCTs, potentially contributing to poorer glycemic outcomes (6,7).

A 2004 systematic review of diabetes medication adherence indicated that 36–93% of patients were adherent (8), but more recent studies have found adherence rates to vary from 20 to 50%, depending on the assessment methods and drug class (9,10). Numerous studies have associated poor medication adherence and problematic long-term persistence (or discontinuation) with poor outcomes for patients with type 2 diabetes, including higher health care costs and utilization and poorer glycemic control (10,11). In contrast, patients enrolled in RCTs may be more likely to take their study medication as directed because of the support provided by the trial, and nonadherent patients are often removed from the published analysis. Patients enrolled in RCTs may also be more motivated to improve their health, leading to better medication adherence and other health-promoting behaviors, and may differ from the broader population of patients with diabetes in ways that influence outcomes (i.e., disease progression or baseline HbA$_{1c}$).

The objective of this study was to compare the change in HbA$_{1c}$ between RW and RCT settings after initiating a glucagon-like peptide 1 receptor agonist (GLP-1 RA) or dipeptidyl peptidase 4 (DPP-4) therapy and determine the factors contributing to any differences observed. Both medication types have demonstrated a significant reduction in HbA$_{1c}$ in RCTs, with additional benefits including lower incidence of hypoglycemia compared with sulfonylureas (12,13). Sodium–glucose cotransporter 2 inhibitors are another new drug class with similar benefits but were excluded owing to the limited number of patients taking sodium-glucose cotransporter 2 inhibitors included in the database used for this study.

To understand the factors associated with differences between RW and trial outcomes, this study compared patient characteristics (e.g., age) and behaviors (e.g., medication adherence). The concept of medication adherence, also called compliance, is intended to assess the degree to which patients follow their health care providers' medication recommendations (e.g., prescribed dose and frequency) during a specified interval of time (14). The critical measure used in this study was based on the percentage of days covered (PDC), which is the most commonly used index in the adherence literature and is used in quality measures endorsed by the National Quality Forum and in Medicare Star ratings (15–17).

RESEARCH DESIGN AND METHODS

This study used simulated trial design framework (18) to compare patients enrolled in RCTs of DPP-4s or GLP-1 RAs with RW patients with type 2 diabetes and estimated a multivariate model of the RW change in HbA$_{1c}$ levels. The estimated model, combined with the descriptive RW and RCT data, was used to describe differences between RCT and RW HbA$_{1c}$ outcomes and the factors contributing to these differences (Supplementary Fig. 1).

RW Data and Patients

The Optum/Humedica SmartFile database (spanning January 2007 to December 2014), one of the largest and most comprehensive integrated databases that includes administrative claims (pharmacy and medical) and electronic medical records, was used to analyze the change in HbA$_{1c}$ (from the electronic medical records) among patients with type 2 diabetes initiating a GLP-1 RA or DPP-4 therapy in RW settings. The index date for each patient was the date of the first prescription fill for a DPP-4 or GLP-1 RA (index drug). The baseline period was the year before the index date, and the follow-up period was the period of ~1 year between the index date and a subsequent HbA$_{1c}$ measurement (± 90 days). Adult patients with type 2 diabetes (aged 18 years at the index date) were included if they had at least one prescription drug fill for a DPP-4 or GLP-1 RA therapy, continuous health plan enrollment (1 year before and after the index date), HbA$_{1c}$ measured at the index date and ~ 1 year later, and if they had key baseline characteristics similar to patients in enrolled in DPP-4 and GLP-1 RA clinical trials (baseline HbA$_{1c}$ between 7 and 10% [53 and 86 mmol/mol] and at least one fill for a type 2 diabetes medication during the baseline period). Patients were excluded if they 1) had a diagnosis of type 1, secondary, or gestational diabetes mellitus during the baseline or follow-up periods; 2) had a fill for insulin during baseline; or 3) were diagnosed with dementia, hemiplegia, liver disease, metastatic solid tumor, AIDS, or a malignancy during baseline or follow-up (diagnosis codes in Supplementary Table 2). Patients initiating a GLP-1 RA or DPP-4 were selected based on National Drug Codes for each ingredient included in each class (GLP-1 RA: exenatide and liraglutide; DPP-4: sitagliptin, saxagliptin, linagliptin, and alogliptin).

The database was compliant with the Health Insurance Portability and Accountability Act. All data were deidentified and thus exempt from institutional board review.

Trial Data

A targeted literature search for published English-language RCTs was performed by searching pharmaceutical manufacturer websites for trials of GLP-1 RAs (liraglutide and exenatide) and DPP-4s (sitagliptin and saxagliptin) in patients with type 2 diabetes. Publications for other DPP-4 therapies (linagliptin and alogliptin) were excluded because <5% of RW DPP-4 patients in the study data set were treated with these drugs. Studies were limited to published manufacturer-sponsored trials because these trials form the basis for efficacy claims.

Inclusion criteria were applied to identify trials evaluating the efficacy of one of the above-listed drugs (often as an add-on therapy) in patients with type 2 diabetes initiating GLP-1 RAs or DPP-4s and previously treated with oral antidiabetic agents but not insulin. Trials in special patient subpopulations were excluded. A list of included and excluded RCTs, with the reason for exclusion, is in Supplementary Table 1. To ensure that the extracted clinical efficacy data reflected the effect of full/standard dosage of the medication, data collected from low-dosage treatment arms (0.6 mg) from two liraglutide trials (19,20) were excluded.

The data elements extracted from RCT publications included average age, baseline HbA$_{1c}$, sex, race, diabetes complications at baseline, type 2 diabetes therapy before GLP-1 RA or DPP-4 initiation, GLP-1 RA or DPP-4 drug and dose, follow-up duration, and change in HbA$_{1c}$. Publications

were also reviewed to describe how the analysis handled patients who discontinued their index medication, did not comply with the drug regimen (poor adherence), or received rescue type 2 diabetes therapies during the follow-up period (e.g., due to high HbA_{1c}).

RW Measures

Change in HbA_{1c} levels was the primary study outcome, measured from a baseline reading near drug initiation (up to 90 days before or 14 days after drug initiation) to a second HbA_{1c} reading 365 ± 90 days after drug initiation (follow-up period). For patients with multiple HbA_{1c} readings near drug initiation, the observation measured closest to the index date was selected. Patients with multiple HbA_{1c} readings ~1 year later (365 ± 90 days) contributed multiple estimates of change in HbA_{1c} but were appropriately weighted to ensure these patients did not contribute disproportionately to study findings.

Baseline characteristics included age (at the index date), baseline HbA_{1c}, use of advanced type 2 diabetes therapies (other than metformin monotherapy), and the presence of diabetes complications during the baseline year. The presence of diabetes complications was assessed based on the Diabetes Complications Severity Index (DCSI) score, a 13-point scale scored from diagnostic and laboratory data that is associated with diabetes progression and greater risk of death (21,22).

Adherence to the index drug was estimated based on the PDC with a nonoverlapping supply of the index drug (GLP-1 RA or DPP-4) during the follow-up period. Consistent with prior literature and standard quality metrics, patients were classified as adherent if the PDC was ≥80% (15–17). This study also measured discontinuation of the index drug, defined by the absence of the index drug on hand for at least 30 days and no subsequent fills through the end of the follow-up period.

Dosing of the index drug during the follow-up period was captured based on the last fill of the index drug in the follow-up period. Patients were classified as receiving at least a full or recommended dose based on each product's prescribing information.

Other changes to the patient's regimen of diabetes drugs (beyond the index drug) were also measured. Specifically, the addition and discontinuation of other (nonindex) type 2 diabetes drugs during the follow-up period was measured by comparing drugs on hand during the 90-day period before the first (index) and second HbA_{1c} measurements. The measure focused on drugs 90 days before each HbA_{1c} measurement because HbA_{1c} measures glycemic control during the previous 3 months; thus, drugs on hand during this interval were most relevant to the observed change in HbA_{1c}.

Analysis of RW Data

The multivariate model estimated the change in HbA_{1c} during the ~1-year follow-up in RW patients, controlling for potentially confounding factors measured at baseline (HbA_{1c}, age, diabetes complications, and use of advanced diabetes therapies) and factors measured during follow-up (indicators of the addition of nonindex type 2 diabetes medications and adherence to the index drug). Sensitivity analyses were conducted to examine 1) the influence of race/ethnicity and sex, which were excluded from the main specification because these factors are correlated with adherence (23,24); and 2) the effect of excluding a measure of the use of advanced diabetes therapies at baseline. The model was estimated using ordinary least squares, and as a linear model, each coefficient demonstrates how much HbA_{1c} levels increased or decreased with every 1-point increase in the value of the covariate.

The estimated coefficients were used to calculate the predicted change in HbA_{1c} levels in trial and RW settings, estimate the gap, and describe factors contributing to the gap. The predicted change in HbA_{1c} in trial settings was calculated by multiplying each estimated coefficient by the value of that covariate in trials and summing the products. The predicted change in HbA_{1c} levels in RW settings can be estimated in the same way and is also mathematically identical to the actual RW change in HbA_{1c} levels. The gap between RW and trial outcomes is the difference between these two predicted values. The contribution of a variable to the gap is the regression coefficient multiplied by differences in the value of that variable observed in patients enrolled in trials and the RW. The predicted HbA_{1c} change in trial settings was compared with estimates extracted from the trials to assess the validity of the model's predicted value. Three sensitivity analyses were conducted to assess how assumptions affect the gap between RW and trial HbA_{1c} outcomes and the role of medication adherence: 1) changes in patient selection criteria (included all patients with $HbA_{1c} >10\%$); 2) assumptions about the percentage of patients in trials with any diabetes complications at baseline (varied from 5 to 30%), and 3) assumptions about medication adherence in trials (varied from 80 to 100%).

The analytic file and descriptive tables were created in SAS (version 7.1), and the regression analysis was conducted in Stata (version 14.2). Significance was assessed at $P < 0.05$. Categorical variables were compared with χ^2 tests and continuous variables with two-sided t tests. To account for multiple outcomes contributed by the same patients, all RW analyses (descriptive and regression analyses) were weighted such that each patient contributed equally to the results (weights were equal to the inverse of the number of HbA_{1c} measurements for a patient). SEs were corrected as appropriate (e.g., clustered SEs) to account for multiple observations of change in HbA_{1c} per patient.

Analysis of Trial Data

The unit of analysis for the trial data was each relevant trial arm (e.g., for a GLP-1 RA or DPP-4), reported as a mean in the trial publication. These reported averages were then pooled, and the weighted average across all of the trials in each drug class was estimated. The reported SEs of the continuous measures (e.g., age, HbA_{1c}) were extracted from each arm, and an estimated grouped SE was calculated for each drug class. Trials that contributed multiple data points (e.g., two arms with different doses) received a weight summing to 1, where the weight was the inverse of the number of trial arms included in the mean. The maximum and minimum change in HbA_{1c} was reported for each drug class.

RESULTS

Trial Publications

A total of 11 RCTs were selected (Supplementary Table 1), composed of 7 GLP-1 RA trials (5 of liraglutide [$n = 2,243$] and 2 of exenatide [$n = 357$]) (19,20,25–29) and 4 DPP-4 trials (2 of sitagliptin [$n = 825$] and 2 of saxagliptin [$n = 845$]) (30–33). A sitagliptin arm

(n = 219) reported in a liraglutide trial (19) was also included. Only 1 of the 11 RCTs reported data on diabetes severity of patients enrolled in the study (25).

Data extracted from the selected RCTs are provided in Supplementary Table 3. All but one of the trials monitored patients for 24–26 weeks (Garber et al. [28] monitored patients for 52 weeks). All of the RCTs included protocols to rescue patients and excluded data from these patients by imputing data after rescue using last observation carried forward or by removing the patients entirely from the analysis, emphasizing the need to control for the addition of other medications in the RW.

RW Data

Among 873 RW patients with type 2 diabetes meeting the inclusion criteria, 652 patients received DPP-4 therapy (contributing 911 observations) (Supplementary Fig. 2), and 221 patients received GLP-1 RA therapy (contributing 297 observations) (Supplementary Fig. 3). About half of GLP-1–treated patients initiated liraglutide (54%), and three-fourths of DPP-4–treated patients initiated sitagliptin. Most patients (80–96%) were receiving the recommended or maximum drug dose (Table 1).

Demographic characteristics were similar across data sources and treatments (Table 1). Baseline HbA$_{1c}$ levels were similar among RW and RCT patients using GLP-1 RAs, but the mean baseline HbA$_{1c}$ of patients in DPP-4 RCTs was lower than in RW patients. Baseline use of advanced therapy was more prevalent among RW patients compared with patients enrolled in RCTs (Table 1), suggesting that RCT patients may be earlier in the progression of type 2 diabetes than RW patients.

RW Medication Use After Initiation of a GLP-1 RA or DPP-4

During the follow-up period, low percentages of RW patients treated with GLP-1 RAs and DPP-4s were adherent to their medications (29% and 37% were adherent, respectively), much lower than would be expected in trials (Table 1).

Approximately one-third of RW patients added another type 2 diabetes medication to their treatment regimen after initiation of GLP-1 RA or DPP-4 therapy (Table 1). These patients included possible rescues (among patients continuing their index drug) and possible

switchers (among patients discontinuing their index drug). Medication discontinuation occurred in 40.3% (DPP-4) to 45.2% (GLP-1 RA) of RW patients (Table 1). Of the patients who discontinued GLP-1 RA or DPP-4 therapy, less than half (44% and 42%, respectively) added another drug, suggesting these patients switched to another medication. Of the RW patients who did not discontinue their GLP-1 or DPP-4 therapy, less than one-third (21% and 29%, respectively) added another drug, suggesting rescue therapy.

Change in HbA$_{1c}$ Levels

The overall unadjusted change in HbA$_{1c}$ levels from baseline was similar among RW users of the two drug classes (GLP-1 RA: −0.52% [6 mmol/mol]; DPP-4: −0.51% [6 mmol/mol]) despite the greater efficacy of GLP-1 RAs demonstrated in RCTs (GLP-1 RA RCTs: −1.30% [−14 mmol/mol]; DPP-4 RCTs: −0.68% [−8 mmol/mol]) (Table 1).

Adherent RW GLP-1 RA patients demonstrated more than double the HbA$_{1c}$ reduction compared with poorly adherent patients, with and without adjustment for potentially confounding factors (Table 1 and Fig. 1). The difference between adherent and poorly adherent patients was smaller for patients treated with a DPP-4.

Coefficients from the regression model used to estimate the change in HbA$_{1c}$ level in RW patients are reported in Table 2 and show that baseline HbA$_{1c}$ levels in both drug classes were important explanatory factors in the change in HbA$_{1c}$ owing to their large (in absolute value terms) and statistically significant coefficients. The coefficient of −0.275 for baseline HbA$_{1c}$ level in the GLP-1 RA regression indicates that for every 1-point increase in baseline HbA$_{1c}$ levels, HbA$_{1c}$ decreased by an additional 0.275% (2 mmol/mol).

Predicted change in HbA$_{1c}$ using the values of covariates in the RCTs estimated a change of −1.03% (−12 mmol/mol) among patients receiving GLP-1 RA and −0.69% (−8 mmol/mol) among patients receiving DPP-4 (Fig. 2). These predicted values were within the range of the mean change in HbA$_{1c}$ levels reported by the RCTs and 95% CIs of most of the selected RCTs. The gap between RW and trial change in HbA$_{1c}$ levels was estimated to be 0.51% (6 mmol/mol; $P < 0.01$) for patients receiving GLP-1 RA therapy and 0.18% (2 mmol/mol; $P = 0.07$) for patients

receiving DPP-4 therapy (Fig. 2). This was calculated as the predicted reduction in HbA$_{1c}$ levels under typical trial conditions (GLP-1 RA: 1.03%; DPP-4: 0.69%) minus the RW change in HbA$_{1c}$ (GLP-1 RA: 0.52%; DPP-4: 0.51%), yielding the gap of 0.51% for GLP-1 RA and 0.18% for DPP-4.

The degree to which each covariate contributed to the estimated gap is presented in Fig. 2. The efficacy gap can be explained by differences in adherence, the addition of another type 2 diabetes drug, and baseline characteristics (including HbA$_{1c}$ levels, use of prior advanced therapy, age, and disease complications). Medication adherence accounted for ~75% (0.39%) of the estimated 0.51% HbA$_{1c}$ gap between RW and RCT patients receiving GLP-1 RA therapy and 72% of the gap between RW and RCT results among DPP-4–treated patients. Other factors may also play a role in explaining the gap between RW and trial outcomes, although any additional contribution to the gap is likely to be much smaller.

Sensitivity Analysis

Sensitivity analyses around the inclusion of other factors in the model, including patients with high baseline HbA$_{1c}$ (>10%) in the RW sample and varying assumptions about adherence and severity of diabetes among trial patients, did not alter conclusions regarding the efficacy gap between RW and RCT patients and the important role of medication adherence in explaining this gap. Previous RW studies have demonstrated sex and race/ethnicity differences in glycemic control among patients with type 2 diabetes, largely driven by differences in medication adherence (34–36). The inclusion of race and sex as variables in the current analysis slightly attenuated the effect of adherence on HbA$_{1c}$ levels (sensitivity model 2 in Table 2). When patients with baseline HbA$_{1c}$ >10% were included (estimates not shown), the estimated effect of adherence on change in HbA$_{1c}$ from baseline became even more negative for the GLP-1 RA cohort but was similar for the DPP-4 cohort (the adherence coefficient changed from −0.581 to −0.706 in the sensitivity analysis in the GLP-1 RA regression and from −0.227 to −0.224 in the DPP-4 regression).

Adherence was assumed to be 95% in clinical trials in all of the results reported thus far. A final sensitivity analyses was conducted using the main model in Table

Table 1—Patient Baseline and Treatment Characteristics and Change in HbA$_{1c}$

	GLP-1 RA		DPP-4	
	RW (*n* = 221)	RCTs[a] (*n* = 2,600)	RW (*n* = 652)	RCTs[a] (*n* = 1,889)
Baseline patient characteristics				
Age (years), mean (SE)	57 (0.71)	56 (0.20)	63 (0.46)	56 (0.22)
Male sex, % (*n*)	58 (127)	53 (1,378)	58 (378)	53 (1,001)
White race, % (*n*)	82 (181)	68 (1,768)	81 (525)	77 (1,455)
HbA$_{1c}$ (%), mean (SE)	8.34 (0.06)	8.41 (0.02)	8.15 (0.03)	7.81 (0.02)
HbA$_{1c}$ (mmol/mol), mean (SE)	67 (0.7)	68 (0.25)	66 (0.3)	62 (0.35)
Any diabetes complications,[b] % (*n*)	62 (136)	15 (390)[c]	62 (401)	15 (283)[c]
Use of advanced type 2 diabetes therapy before index,[d] % (*n*)	83 (184)	50 (1,300)	71 (460)	7 (132)
Treatment characteristics during follow-up				
Adherent to index drug, % (*n*)	29 (64)[e]	95 (2,470)[e]	37 (242)	95 (1,795)[f]
Discontinued index drug, % (*n*)	45 (100)[g,h]	0 (0)	40 (263)[g,h]	0 (0)
Switched to another class of diabetes drug, % of patients who discontinued (*n*)	44 (44)	—	42 (110)	—
Did not discontinue index drug, % (*n*)	55 (121)[g,h]	100 (2,600)	60 (389)[g,h]	100 (1,889)
Added new diabetes medication and continued index therapy (e.g., rescue therapy), % of patients who did not discontinue (*n*)	21 (26)	—	29 (114)	—
Addition of other type 2 diabetes drug(s) after GLP-1 RA/DPP-4 initiation, % (*n*)	32 (70)[h]	0 (0)[i]	34 (224)[h]	0 (0)[i]
Change in HbA$_{1c}$ level ∼1 year after drug initiation				
Level difference (%), mean (95% CI) [range]	−0.52 (−0.66, −0.38)	−1.30 [−1.60, −0.84][j]	−0.51 (−0.59, −0.43)	−0.68 [−0.90, −0.47][j]
Level difference (mmol/mol), mean (95% CI) [range]	−6 (−16.3, −27.6)	−14 [−18, −9][j]	−6 (−17.1, −28.2)	−8 [−10, −5][j]

[a]Information from seven GLP-1 RA and four DPP-4 trials was extracted. One GLP-1 RA trial was a head-to-head comparison against a DPP-4 agent (19). Data for both treatment arms were extracted. [b]Patients were considered to have diabetes complications if their DCSI score was greater than 1 (22) and included the following seven categories of complications: cardiovascular disease, nephropathy, retinopathy, peripheral vascular disease, stroke, neuropathy, and metabolic. [c]Patients in GLP-1 RA and DPP-4 trials were assumed to have a similar percentage of patients with any diabetes complications as to the percentage reported in one of the selected GLP-1 RA trials (25). [d]Use of advanced diabetes medications was defined as equal to 1 if the patient was treated with any monotherapy or combination of type 2 diabetes drugs beyond metformin monotherapy and defined as equal to 0 if the patient was treated with metformin monotherapy during the baseline year. [e]For patients with multiple treatment measurements due to multiple weight measurements eligible for the study, PDC was weighted by the number of observations per patient. [f]Medication adherence was not widely reported in RCTs and was assumed to be 95% based on information reported in the included RCTs (see Supplementary Table 1). [g]Discontinuation was defined by the absence of the index drug on hand for at least 30 days and until the second HbA$_{1c}$ measurement date. [h]For patients with multiple treatment measurements due to multiple HbA$_{1c}$ measurements eligible for the study, discontinuation and treatment augmentation associated with the latest observation of each patient were reported. [i]Because data after patients receive additional diabetes drugs (e.g., rescue therapy) are excluded from analyses of trial data, the addition of type 2 diabetes drugs post index in trial settings was assumed to be zero for the purpose of predicting change in HbA$_{1c}$ under typical trial conditions. [j]Owing to the lack of individual patient-level data of RCTs, ranges of change in HbA$_{1c}$ were reported for GLP-1 RA and DPP-4 studies, respectively.

2 and varying the assumed adherence in trials from 80 to 100%. This sensitivity analysis found that adherence accounted for 72–75% of the gap, similar to the main findings.

CONCLUSIONS

Our findings demonstrate that the efficacy observed in GLP-1 RA and DPP-4 RCTs in patients with type 2 diabetes has not been fully realized in RW settings for either drug class, and poor medication adherence is a key reason. These results are consistent with a recent study of RW glycemic control in patients treated with liraglutide, which found an 0.80% reduction in HbA$_{1c}$ among adherent patients and half that (0.42%) among poorly adherent patients (10)—similar to findings reported here for GLP-1–treated patients, more than half of whom were treated with liraglutide. Patients included in that study also had similar characteristics to

this study: baseline HbA$_{1c}$ was 8.22% (vs. 8.34% currently) and 34% of patients were adherent (vs. 29%) (10).

Four additional publications have examined RW change in HbA$_{1c}$ among patients treated with liraglutide, exenatide, sitagliptin, and DPP-4s as a class (37–40); none of these examined the role of medication adherence, and the patient populations differed from our study and previous study of medication adherence (10). Two of these studies selected patients that may bias toward patients more adherent than typical by requiring patients to have at least 3 months of fills and 6 months of follow-up (38,39). These two studies reported a change in HbA$_{1c}$ of −1% to −0.9% for liraglutide, 0.68% for exenatide, and 0.63% for sitagliptin, similar to our findings among adherent RW patients, or a little lower in the case of exenatide (our study showed reduction

of 0.86% for GLP-1s and 0.60% for DPP-4s). In addition, these studies reported HbA$_{1c}$ reductions for liraglutide-treated patients and DPP-4–treated patients that were similar to adherent patients in our study. These two studies also monitored patients for less than 1 year (6–9 months) but did not appear to have required patients to have a minimum number of fills to be included (37,40). One study was limited to a single employer, and the other used matching techniques to select DPP-4–treated patients who were similar to patients treated with canagliflozin (this comparison was the focus of the study), potentially limiting the generalizability of the study to a broader patient population treated with a DPP-4 or liraglutide.

An additional study conducted in Europe, by Ahrén et al. (41), is worth noting because it explicitly compared trial HbA$_{1c}$ outcomes with outcomes among patients

Figure 1—Change in HbA_{1c} among RW patients overall and by adherence to GLP-1 RA (A) and to DPP-4 (B).

treated with vildagliptin enrolled in a prospective "real-life" observational study. Ahrén et al. found that "real-life" patients treated with vildagliptin experienced similar reductions in HbA_{1c} as those enrolled in RCTs. However, these patients chose to enroll in a trial and may have had greater motivation to treat their diabetes and remain adherent to medication than typical RW patients. We, therefore, conclude that our finding that efficacy in RCTs is often not realized in RW settings, with poor medication adherence as a key explanatory factor, is consistent with prior literature.

This study identified medication adherence as a key explanatory factor for the gap between RW effectiveness and RCT efficacy. A drug cannot be expected to provide full benefit if the recommended therapeutic dose is not taken by the patient consistently. Reasons for poor adherence are likely multifactorial and have been previously noted to include issues such as adverse effects, cost, and patients' medication beliefs (42). A large fraction of patients taking both oral (GLP-1) and injectable (DPP-4) agents were not adherent in this study. These routes of administration may be difficult

to maintain for long periods in the treatment of chronic diseases such as type 2 diabetes. Innovation in dose delivery modality, particularly dose regimen simplification, has been previously associated with improved patient adherence via reduced dosing frequency, a lower rate of adverse effects, and increased safety (43–45).

The findings of this study should be considered in light of several limitations. First, patients were not randomly assigned to RW versus RCT settings; RW patients may differ in ways that may affect the ability to achieve lower glucose

Table 2—Estimated coefficients from the multivariate linear regression model of RW change in HbA1c levels ~1 year after initiation

	Multivariate regression estimates					
	Main model		Sensitivity model 1		Sensitivity model 2	
Patient sample by index drug class	GLP-1 RA	DPP-4	GLP-1 RA	DPP-4	GLP-1 RA	DPP-4
Covariates						
Patient characteristics						
Measured at index date						
Baseline HbA1c	−0.275 (0.114)**	−0.484 (0.065)***	−0.265 (0.117)**	−0.446 (0.067)***	−0.254 (0.115)**	−0.475 (0.066)***
Age	0.006 (0.009)	−0.016 (0.005)***	0.007 (0.009)	−0.011 (0.004)**	0.007 (0.008)	−0.017 (0.005)***
Measured during baseline year						
Use of advanced diabetes medications[a]	0.599 (0.201)***	0.468 (0.109)***	0.598 (0.197)***	0.484 (0.110)***	0.598 (0.197)***	0.484 (0.110)***
Any diabetes complications[b]	−0.022 (0.149)	0.070 (0.102)	−0.003 (0.152)	0.113 (0.101)	0.007 (0.149)	0.085 (0.104)
Treatment characteristics, measured during follow-up[c]						
Addition of other (nonindex) type 2 diabetes drugs[d]	−0.285 (0.162)*	−0.039 (0.100)	−0.267 (0.166)	−0.021 (0.101)	−0.241 (0.158)	−0.051 (0.099)
Adherence to index drug[e]	−0.581 (0.176)***	−0.227 (0.085)***	−0.565 (0.180)***	−0.192 (0.086)**	−0.535 (0.173)***	−0.206 (0.086)**
White (Ref: Nonwhite)					−0.441 (0.232)*	−0.070 (0.117)
Male (Ref: Female)					−0.321 (0.160)**	−0.197 (0.098)**
Constant	1.769 (1.108)	4.597 (0.629)***	1.547 (1.134)	3.833 (0.615)***	2.093 (1.124)*	4.769 (0.640)***
Observations, n	297	911	297	911	297	911
Patients, n	221	652	221	652	221	652
Adjusted R^2	0.087	0.103	0.057	0.077	0.114	0.107

The models were estimated using a weighted linear regression with clustered SEs to account for multiple observations per patient. Weights were set as the inverse of the number of the patient's observations so that weights for each patient summed to 1 and each patient's data contributed equally to the analysis. SEs are presented in parentheses. Ref, reference. ***$P < 0.01$, **$P < 0.05$, *$P < 0.1$. [a]Use of advanced diabetes medications was defined as equal to 1 if the patient was treated with any monotherapy or combination of type 2 diabetes drugs beyond metformin monotherapy during the baseline year. [b]Any diabetes complications was defined as 1 if patients the DCSI score was ≥1 (22). [c]Covariates measured during follow-up were measured between the index HbA1c measurement and the subsequent measured used to calculate change in HbA1c levels and could vary within patients with multiple change in HbA1c estimates. For example, a patient may be adherent at the first change in HbA1c reading but may be classified as poorly adherent at a later change in HbA1c reading. [d]Addition of another type 2 diabetes drugs after initiation was defined as 1 if additional drug classes were added after initiation of the index drug. [e]Adherence to index drug was defined as the percentage of days covered by GLP-1 RA or DPP-4 ≥80%.

levels. Although we examined important parameters that can be measured and observed in the RW data, unobservable factors, such as disease duration and extent of progression, could bias results. RW patients appeared to be further progressed (more were previously treated with an advanced therapy compared with RCT patients), and these patients continued taking these therapies during follow-up. We controlled for the use of prior advanced therapy in the regression model, but it is possible that this metric did not capture the full affect of later use (and possibly poorer β-cell function), potentially understating the gap in glycemic benefit between RW and trial outcomes. RW patients may take more medications and have more comorbid conditions; these factors could contribute to the poor adherence observed in the RW, although the reasons for poor RW adherence were not examined in this study. There is evidence that older patients are more adherent to their diabetes medications (23). However, this study controlled for age, so this is unlikely to significantly bias results. Second, data on the use of medication samples were not available in the database. Third, medication adherence is likely overstated in claims data because administrative claims only measure filled prescriptions; not all medications dispensed can be confirmed to be taken by the patient. This is also likely to understate the role of adherence in explaining differences in outcomes in the RW and trial settings. Fourth, because this study did not control for differences between DPP-4– and GLP-1 RA–treated patients, comparisons across classes should be made with caution. The similar percentage of the gap explained by adherence for the two drug classes is likely an artifact of choosing the RW change in HbA1c as the denominator of this percentage. Finally, although adherence to GLP-1 RA or DPP-4 was the study's focus, many patients were taking other medications (e.g., metformin), and adherence to these drugs could affect results.

In conclusion, this study found that patients with type 2 diabetes receiving GLP-1 RA and DPP-4 therapies suffer from poorer outcomes in RW settings compared with their counterparts in RCTs, signifying an important gap in efficacy/effectiveness between trials and the RW. This result is unsurprising because numerous studies have documented differences between trial efficacy and RW

Figure 2—Observed RW, modeled, and published trial estimates of HbA1c change from baseline. The addition of other type 2 diabetes medications post index reduced the efficacy gap by 17% for GLP-1 RA (A) and 5% for DPP-4 (B). Adherence in RCTs was assumed to be 95%. [a]Baseline patient characteristics include age, baseline HbA1c, drug therapy, and any diabetes complications. [b]Trial change in HbA1c reported in Garber et al. (28). [c]Trial change in HbA1c reported in Blevins et al. (27). [d]Trial change in HbA1c reported in Arechavaleta et al. (32). [e]Trial change in HbA1c reported in Pratley et al. (19).

effectiveness (46). The contribution of this report is to identify reasons for this difference. The multivariate model used in this study showed poor medication adherence was the most important reason for the lower effectiveness observed in the RW, which may also extend to other classes of type 2 diabetes medications. Glycemic control data have only recently become available in large RW databases. Future studies of RW outcomes in diabetes should measure and account for medication adherence, because this can be an important confounding factor. Oral and injectable administration routes both rely on consistent patient action to maintain adherence, yet studies such as this one frequently find low adherence rates. For chronic diseases such as type 2 diabetes, effective measures for improving adherence are often complex combinations

of patient education, reminders, reinforcement, and convenience (47,48), which will necessitate sophisticated coordination of care (49). The results of this study indicate an urgent need for strategies to improve RW medication adherence so patients with type 2 diabetes can realize the full benefit of therapy and achieve optimal health outcomes.

References

1. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613–1624
2. Carls G, Huynh J, Tuttle E, Edelman S. Achievement of glycated hemoglobin goals in the U.S. remains unchanged through 2014. Presented at the 76th Scientific Sessions of the American Diabetes Association, 10–14 June 2016, at the Ernest N. Morial Convention Center, New Orleans, LA
3. U.S. Food and Drug Administration. FDA-approved diabetes medicines [article online]. Available from https://www.fda.gov/ForPatients/Illness/Diabetes/ucm408682.htm. Accessed 18 September 2017
4. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140–149

5. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379
6. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff (Millwood) 2010;29:1818–1825
7. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?" Lancet 2005;365:82–93
8. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218–1224
9. Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014;31:1287–1305
10. Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: a retrospective cohort study. Adv Ther 2015;32:341–355
11. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 2011;33:74–109
12. Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012;344:d7771
13. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378–388
14. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–47
15. Centers for Medicare & Medicaid Services (CMS). Medicare 2015 Part C & D Star Rating Technical Notes [Internet], 2015. Available from http://cdn5.medicarehelp.org/wp-content/uploads/2014/10/2015_Tech_Notes_2014_10_03.pdf. Accessed 3 March 2016
16. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836–1841
17. National Quality Forum (Ed.). National Quality Forum (NQF)-Endorsed Measures for Endocrine Conditions, 2013-2015: Final Report. Technical Report. Washington, DC, National Quality Forum, 2015
18. Toh S, Manson JE. An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease. Stat Biosci 2013;5: 10.1007/s12561-012-9073-6
19. Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with

metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447–1456
20. Nauck M, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84–90
21. Singhal M, Nguyen H, Schauerhamer M, Unni S, Cobden D, McAdam-Mark C. Effect of daily or weekly GLP-1 receptor agonists on glycemic control in insulin-naïve patients with poorly controlled type 2 diabetes: a real-world study. Poster presented at the ISPOR 20th Annual International Meeting, 16–20 May 2015, at the Philadelphia Marriott Downtown, Philadelphia, PA
22. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15–23
23. Curkendall SM, Thomas N, Bell KF, Juneau PL, Weiss AJ. Predictors of medication adherence in patients with type 2 diabetes mellitus. Curr Med Res Opin 2013;29:1275–1286
24. Kountz D. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups. Adv Ther 2013;30:1067–1085
25. Marre M, Shaw J, Brändle M, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268–278
26. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234–2243
27. Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301–1310
28. Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373: 473–481
29. Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224–1230
30. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194–205
31. DeFronzo RA, Hissa MN, Garber AJ, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649–1655

32. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160–168

33. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619–1631

34. Manan MM, Husin AR, Alkhoshaiban AS, Al-Worafi YM, Ming LC. Interplay between oral hypoglycemic medication adherence and quality of life among elderly type 2 diabetes mellitus patients. J Clin Diagn Res 2014;8:JC05–JC09

35. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 2004;27:2800–2805

36. Zhu VJ, Tu W, Marrero DG, Rosenman MB, Overhage JM. Race and medication adherence and glycemic control: findings from an operational health information exchange. AMIA Annu Symp Proc 2011;2011:1649–1657

37. Chitnis AS, Ganz ML, Benjamin N, Langer J, Hammer M. Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study. Adv Ther 2014;31:986–999

38. Li Q, Chitnis A, Hammer M, Langer J. Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States. Diabetes Ther 2014; 5:579–590

39. DeKoven M, Lee WC, Bouchard J, Massoudi M, Langer J. Real-world cost-effectiveness: lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Adv Ther 2014;31: 202–216

40. Thayer S, Chow W, Korrer S, Aguilar R. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors. Curr Med Res Opin 2016;32:1087–1096

41. Ahrén B, Mathieu C, Bader G, Schweizer A, Foley JE. Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia 2014;57: 1304–1307

42. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag 2005;1:189–199

43. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence 2013;7:419–434

44. Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes [published correction appears in Clin Ther 2015;37:1870]. Clin Ther 2003;25:2307–2335; discussion 2306

45. Shi L, Hodges M, Yurgin N, Boye KS. Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006). Expert Rev Pharmacoecon Outcomes Res 2007;7:187–202

46. Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol 2014;5:e45

47. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008

48. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014

49. Bodenheimer T. Coordinating care—a perilous journey through the health care system. N Engl J Med 2008;358:1064–1071